Quinases dependentes de ciclinas (CDKs) compreendem uma família de proteínas que podem ser subdivididas em dois grupos funcionais majoritários baseados na sua função no ciclo celular e/ou controle transcricional. Já foram identificadas mais de 30 CDKs humanas. A CDK10 é uma proteína quinase dependente de ciclina pertencente ao grupo de quinases relacionadas à Cdc2. CDK10 é essencial na fase G2/M do ciclo celular, possivelmente no progresso dessa fase, monitorando a replicação completa do DNA e permitindo que as células passem desse ponto de restrição. Essa proteína é um importante determinante de resistência à terapia endócrina para câncer de mama. Portanto, é um alvo potencial para o desenvolvimento de inibidores, uma vez que está presente em células cancerosas. O estudo da estrutura e função da CDK10 deverá ser realizado após sua clonagem, expressão e purificação. O cDNA da CDK10 foi amplificado por reação em cadeia da polimerase (PCR), e posteriormente, o produto foi aplicado em gel de agarose para análise e purificação. O vetor de clonagem recombinante foi obtido, o qual foi clonado em células competentes e sequenciado. A obtenção do plasmídeo recombinante para expressão deu-se pela inserção do DNA nos vetores de expressão pET28a(+) e pET23a(+) (Novagen). A proteína foi expressa em células competentes e analisada por eletroforese em gel de poliacrilamida. Em seguida, a proteína obtida foi purificada em coluna de afinidade por níquel e em coluna de afinidade por ATP. Com a otimização dos resultados obtidos, será possível, futuramente, caracterizar bioquimicamente a CDK10 e elucidar suas estruturas secundária e terciária. O estudo da CDK10 irá contribuir para o entendimento da sua relação estrutura-função e sua relação com oncogenes e supressores de tumor, e o estudo estrutural para o desenvolvimento de inibidores químicos de baixo peso molecular que possa inibir especificamente a CDK10. / Cyclin-dependent kinases (CDKs) comprise a family of proteins that can be subdivided into two major groups based on their functional role in cell cycle and / or transcriptional control. Over 30 human CDKs have been identifies. CDK10 is a cyclin-dependent kinase protein that belongs to the cdc2-related kinases group. CDK10 is essential in phase G2 / M of the cell cycle, possibly in the progress of this phase, monitoring the complete DNA replication and allowing the cells to pass through this restriction point. This protein is an important determinant of resistance to endocrine therapy for breast cancer. Therefore, it is a potential target for the development of inhibitors, since it is present in cancerous cells. The study of the structure and function of CDK10 must be performed after its cloning, expression and purification. cDNA of CDK10 was amplified by polymerase chain reaction (PCR) and then the product was applied into agarose gel for analysis and purification The cloning vector was obtained, which was cloned into competent cells and sequenced. The obtaining of the recombinant plasmid for expression was due to the insertion of DNA into expression vectors pET28a(+) and pET23a(+) (Novagen). The protein was expressed in competent cells and analyzed by electrophoresis on polyacrylamide gel. Then, the obtained protein was purified by nickel affinity column and ATP affinity column. With the optimization of the results obtained, it will be possible, in the future, to biochemically characterize CDK10 and elucidate its secondary and tertiary structures. The study of CDK10 will contribute to the understanding of its structure-function relationship and its relationship with oncogenes and tumor suppressors, and the structural study for the development of low molecular weight chemical inhibitors that can specifically inhibit CDK10. The structural studies will contribute to the development of chemical inhibitors of low molecular weight that may this and other CDKs.

La déficience intellectuelle (DI) touche 1 à 3% de la population générale avec un excès de sujets de sexe masculin. Cette affection est caractérisée par une extrême hétérogénéité clinique et génétique rendant son élucidation complexe. La révolution technologique des outils permettant l’analyse du génome intervenue depuis les années 2000 avec l’analyse chromosomique sur microréseau et singulièrement depuis 2010 avec les applications du séquençage à haut débit a considérablement facilité l’identification de nouveaux gènes. Nous avons tiré avantage de ce phénomène pour identifier trois affections neurologiques à caractère familial Nous avons procédé selon une méthodologie structurée pour conduire, grâce à la mise en place d’un réseau de collaborations, à la découverte ou à la confirmation de l’existence de nouvelles formes de DI. 1.Séquençage de l'exome couplé à la recherche de variations du nombre de copies 2. Mise à jour d’une altération de séquence génique potentiellement causale retrouvée chez le cas index et chez les autres sujets atteints de la famille 3.Extension des résultats à d’autres familles par la constitution d’une cohorte de réplication 4.Élaboration d’une série d’études fonctionnelles venant conforter l’hypothèse de causalité par la création d’un modèle animal et/ou la réalisation d’études biochimiques spécifiquesL’application de cette méthodologie nous a permis de conduire à terme trois projets : L’individualisation d’une forme syndromique de DI récessive autosomique associée à une malformation du rachis cervical et liée aux mutations bi-alléliques de CDK10. La caractérisation d’une encéphalopathie récessive autosomique létale associée à une hypertonie sévère et à une arthrogrypose distale liée aux mutations bi-alléliques d’ATAD1. L’implication de FRMPD4 dans une nouvelle forme de DI non syndromique liée à l’X / Intellectual disability (ID) impacts 1 to 3% of the general population with an excess of affected males. This condition is characterized by an extreme clinical and genetic heterogeneity making the deciphering of its causes more complex. The technological revolution that took place in the study of the genome over the last two decades has provided a useful tool for identification of new genetic entities. This is particularly true for chromosomal micro-array analysis since early 2000s and for next generation sequencing since 2011. We took advantage of this by identifying the molecular basis of three singular conditions. We applied a structured methodology and created a network of collaborations to define or confirm these new ID syndromes. 1. Whole exome sequencing alongside with array-CGH 2.Identification of a candidate gene sequence alteration in the index case and other affected patients of the family 3.Constitution and study of a replication cohort 4.Biochemical studies and/or animal models in order to support the assumption of causalityBased on this research strategy, we were able to complete the following projects : Discovery of a syndromic form of autosomal recessive ID associated with cervical spine defects due to bi-allelic CDK10 mutations. Identification of an ATAD1-related profound and lethal autosomal recessive encephalopathy with stiffness and distal arthrogryposis. Characterization of a FRMPD4-related X-linked non-syndromic ID

Quinases dependentes de ciclinas (CDKs) compreendem uma família de proteínas que podem ser subdivididas em dois grupos funcionais majoritários baseados na sua função no ciclo celular e/ou controle transcricional. Já foram identificadas mais de 30 CDKs humanas. A CDK10 é uma proteína quinase dependente de ciclina pertencente ao grupo de quinases relacionadas à Cdc2. CDK10 é essencial na fase G2/M do ciclo celular, possivelmente no progresso dessa fase, monitorando a replicação completa do DNA e permitindo que as células passem desse ponto de restrição. Essa proteína é um importante determinante de resistência à terapia endócrina para câncer de mama. Portanto, é um alvo potencial para o desenvolvimento de inibidores, uma vez que está presente em células cancerosas. O estudo da estrutura e função da CDK10 deverá ser realizado após sua clonagem, expressão e purificação. O cDNA da CDK10 foi amplificado por reação em cadeia da polimerase (PCR), e posteriormente, o produto foi aplicado em gel de agarose para análise e purificação. O vetor de clonagem recombinante foi obtido, o qual foi clonado em células competentes e sequenciado. A obtenção do plasmídeo recombinante para expressão deu-se pela inserção do DNA nos vetores de expressão pET28a(+) e pET23a(+) (Novagen). A proteína foi expressa em células competentes e analisada por eletroforese em gel de poliacrilamida. Em seguida, a proteína obtida foi purificada em coluna de afinidade por níquel e em coluna de afinidade por ATP. Com a otimização dos resultados obtidos, será possível, futuramente, caracterizar bioquimicamente a CDK10 e elucidar suas estruturas secundária e terciária. O estudo da CDK10 irá contribuir para o entendimento da sua relação estrutura-função e sua relação com oncogenes e supressores de tumor, e o estudo estrutural para o desenvolvimento de inibidores químicos de baixo peso molecular que possa inibir especificamente a CDK10. / Cyclin-dependent kinases (CDKs) comprise a family of proteins that can be subdivided into two major groups based on their functional role in cell cycle and / or transcriptional control. Over 30 human CDKs have been identifies. CDK10 is a cyclin-dependent kinase protein that belongs to the cdc2-related kinases group. CDK10 is essential in phase G2 / M of the cell cycle, possibly in the progress of this phase, monitoring the complete DNA replication and allowing the cells to pass through this restriction point. This protein is an important determinant of resistance to endocrine therapy for breast cancer. Therefore, it is a potential target for the development of inhibitors, since it is present in cancerous cells. The study of the structure and function of CDK10 must be performed after its cloning, expression and purification. cDNA of CDK10 was amplified by polymerase chain reaction (PCR) and then the product was applied into agarose gel for analysis and purification The cloning vector was obtained, which was cloned into competent cells and sequenced. The obtaining of the recombinant plasmid for expression was due to the insertion of DNA into expression vectors pET28a(+) and pET23a(+) (Novagen). The protein was expressed in competent cells and analyzed by electrophoresis on polyacrylamide gel. Then, the obtained protein was purified by nickel affinity column and ATP affinity column. With the optimization of the results obtained, it will be possible, in the future, to biochemically characterize CDK10 and elucidate its secondary and tertiary structures. The study of CDK10 will contribute to the understanding of its structure-function relationship and its relationship with oncogenes and tumor suppressors, and the structural study for the development of low molecular weight chemical inhibitors that can specifically inhibit CDK10. The structural studies will contribute to the development of chemical inhibitors of low molecular weight that may this and other CDKs.